BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shanghai Auzone Biological Technology readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Shanghai Auzone Biological Techno
 logy's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07252440-784@assetmemo.bio
DTSTAMP:20261121T005939Z
DTSTART;VALUE=DATE:20281023
DTEND;VALUE=DATE:20281024
SUMMARY:Edaravone (TTYP01): Phase 2 readout est. (NCT07252440)
DESCRIPTION:Edaravone (TTYP01)\, phase 2\, Alzheimer's Disease.\nStudy: A S
 tudy to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Sympto
 matic Alzheimer's Disease\nEstimated primary completion: 23 October 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/edaravone-ttyp01#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07252440
URL:https://assetmemo.bio/drug/edaravone-ttyp01#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
